Report Description Table of Contents How Are ICD Protection and Advanced Ablation Reshaping the Brugada Syndrome Treatment Market? The Global Brugada Syndrome Treatment Market was valued at USD 268 million in 2025 and is projected to reach USD 436 million by 2032, expanding at a CAGR of 7.2% during 2026–2032, according to Strategic Market Research. Brugada syndrome is a rare inherited heart-rhythm disorder that can trigger dangerous ventricular arrhythmias, fainting, cardiac arrest, and sudden cardiac death. In the United States, the condition is estimated to affect fewer than 1 in 5,000 people, suggesting that fewer than 66,000 Americans may be living with Brugada syndrome. Diagnosis remains difficult because many patients are asymptomatic until an ECG identifies the characteristic electrical pattern or a serious cardiac event occurs. The disorder is also reported to be around 8–10 times more common in men than women. Treatment is centered on preventing life-threatening arrhythmias. Implantable cardioverter-defibrillators (ICDs) remain the main therapy for patients who have survived cardiac arrest or are considered at high risk. ICDs continuously monitor heart rhythm and deliver an electrical shock when a dangerous rhythm is detected. Quinidine may be used to reduce recurrent arrhythmias, while isoproterenol can be administered in hospital settings during severe electrical storms. Catheter ablation is increasingly used in selected patients with repeated ventricular arrhythmias or recurrent ICD shocks. Market expansion is supported by improved ECG-based detection, genetic and family screening, wider access to electrophysiology care, and greater use of ICDs and catheter ablation. Clinical awareness is also important because Brugada syndrome has been associated with an estimated 4%–12% of sudden cardiac deaths in people with structurally normal hearts, increasing the need for earlier diagnosis, risk assessment, and long-term rhythm management. Why Do ICDs Lead the Brugada Syndrome Treatment Market While Catheter Ablation Expands Fastest? By Treatment Type Implantable Cardioverter-Defibrillators (ICDs) account for an estimated 58% share, equivalent to approximately USD 155.4 million in 2025, and are projected to expand at a CAGR of approximately 6.7% during 2026–2032. ICDs remain the leading treatment option for high-risk patients with previous cardiac arrest, documented ventricular fibrillation, or serious arrhythmic events. Epicardial Radiofrequency Ablation represents approximately 19% share, corresponding to around USD 50.9 million in 2025, and is projected to record the fastest CAGR of approximately 10.2% during 2026–2032. Increasing use among patients experiencing recurrent ventricular fibrillation, electrical storms, and repeated ICD shocks supports the segment. Antiarrhythmic Drug Therapy, including quinidine and related pharmacological management, holds an estimated 16% share, representing approximately USD 42.9 million in 2025, and is projected to expand at a CAGR of approximately 6.3% during 2026–2032. Emergency and Supportive Rhythm Management, including isoproterenol-based treatment for electrical storms and associated cardiac monitoring, accounts for approximately 7% share, equivalent to around USD 18.8 million in 2025, and is projected to expand at a CAGR of approximately 5.8% during 2026–2032. By Diagnosis Method Electrocardiography and Provocative Drug Testing hold the leading 46% share, representing approximately USD 123.3 million in 2025, and are projected to expand at a CAGR of approximately 6.3% during 2026–2032. ECG remains central to identifying characteristic Brugada electrical patterns, while provocative testing can uncover concealed cases among patients with suspected disease. Electrophysiological Testing and Mapping account for approximately 32% share, equivalent to around USD 85.8 million in 2025, and are expected to record the fastest CAGR of approximately 8.3% during 2026–2032. Greater use of electro-anatomic and substrate mapping before catheter ablation is increasing the clinical importance of electrophysiological evaluation. Genetic Testing represents approximately 22% share, generating around USD 59.0 million in 2025, and is projected to expand at a CAGR of approximately 7.6% during 2026–2032. Family screening and identification of inherited abnormalities such as SCN5A variants continue to support genetic assessment among diagnosed patients and close relatives. By End User Hospitals hold a dominant 68% share, representing approximately USD 182.2 million in 2025, and are projected to expand at a CAGR of approximately 6.8% during 2026–2032. Hospitals remain the principal treatment setting because serious Brugada syndrome cases can require emergency cardiac care, continuous ECG monitoring, electrophysiology studies, ICD implantation, catheter ablation, and intensive arrhythmia management. Specialty Cardiac and Electrophysiology Centers b?account for approximately 22% share, equivalent to around USD 59.0 million in 2025, and are projected to record the fastest CAGR of approximately 8.4% during 2026–2032. Concentrated expertise in inherited arrhythmias, electro-anatomic mapping, ICD management, and complex ablation supports their expanding role. Ambulatory and Specialized Outpatient Centers represent approximately 10% share, corresponding to around USD 26.8 million in 2025, and are projected to expand at a CAGR of approximately 7.5% during 2026–2032, primarily through follow-up evaluation, cardiac monitoring, diagnostic assessment, and device-management services. By Geography North America holds an estimated 36% share, representing approximately USD 96.5 million in 2025, and is projected to expand at a CAGR of approximately 6.7% during 2026–2032. Broad access to ICD implantation, established electrophysiology infrastructure, inherited-arrhythmia programs, and specialist cardiac monitoring supports the region's leading commercial position. Europe accounts for approximately 29% share, equivalent to around USD 77.7 million in 2025, and is projected to expand at a CAGR of approximately 6.8% during 2026–2032. Established electrophysiology centers and structured inherited cardiac-condition programs support continued treatment activity. Asia-Pacific represents approximately 27% share, corresponding to around USD 72.4 million in 2025, and is projected to record the fastest regional CAGR of approximately 8.4% during 2026–2032. Higher reported Brugada syndrome prevalence in Southeast Asian populations, improving electrophysiology infrastructure, and wider access to ICD implantation and ablation are increasing treatment activity across the region. Latin America contributes approximately 5% share, equivalent to around USD 13.4 million in 2025, and is projected to expand at a CAGR of approximately 6.9% during 2026–2032. Middle East & Africa account for approximately 3% share, representing around USD 8.0 million in 2025, and are projected to expand at a CAGR of approximately 6.3% during 2026–2032. Which Segments Are Leading and Expanding Fastest in the Brugada Syndrome Treatment Market? By Treatment Type: ICDs Anchor Care as Epicardial Ablation Accelerates Leading Subsegment – Implantable Cardioverter-Defibrillators (ICDs) Implantable cardioverter-defibrillators form the largest treatment segment in the Brugada Syndrome Treatment Market, accounting for an estimated 58% share and approximately USD 155.4 million in 2025, with a projected CAGR of approximately 6.7% during 2026–2032. ICDs remain the primary life-saving treatment for high-risk patients because they continuously monitor heart rhythm and can deliver an electrical shock when a dangerous ventricular arrhythmia develops. Their central role in preventing sudden cardiac death keeps ICD implantation at the core of long-term treatment for patients with previous cardiac arrest, ventricular fibrillation, or other serious arrhythmic events. Fastest-Growing Subsegment – Epicardial Radiofrequency Ablation Epicardial radiofrequency ablation accounts for an estimated 19% share, representing approximately USD 50.9 million in 2025, and is projected to register the fastest CAGR of approximately 10.2% during 2026–2032. The procedure targets abnormal electrical substrate on the outer surface of the right ventricular outflow tract and can reduce recurrent life-threatening ventricular arrhythmias. Its use is particularly important among patients experiencing repeated ventricular fibrillation, electrical storms, or recurrent ICD shocks despite conventional treatment. By Diagnosis Method: ECG Detection Leads as Precision Mapping Gains Ground Leading Subsegment – Electrocardiography and Provocative Drug Testing Electrocardiography and Provocative Drug Testing account for approximately 46% of the market, representing USD 123.3 million in 2025, and are projected to expand at a CAGR of approximately 6.3% during 2026–2032. ECG identifies characteristic electrical abnormalities associated with Brugada syndrome, while provocative testing using controlled sodium-channel-blocking drugs can reveal concealed cases. Identifying affected patients through these methods can lead directly to closer rhythm monitoring, electrophysiology assessment, medication management, or ICD treatment among those considered at elevated risk. Fastest-Growing Subsegment – Electrophysiological Testing and Mapping Electrophysiological Testing and Mapping account for an estimated 32% share, representing approximately USD 85.8 million in 2025, and are projected to register the fastest CAGR of approximately 8.3% during 2026–2032. Electrophysiological studies and electro-anatomic mapping allow specialists to identify abnormal electrical substrate associated with ventricular arrhythmias. Increasing use of substrate-guided epicardial ablation is making detailed mapping more important in the treatment pathway for selected high-risk Brugada syndrome patients. By End User: Hospitals Lead as Specialist Centers Expand Complex Care Leading Subsegment – Hospitals Hospitals hold an estimated 68% share of the Brugada Syndrome Treatment Market, representing approximately USD 182.2 million in 2025, and are projected to expand at a CAGR of approximately 6.8% during 2026–2032. Hospitals remain the principal treatment setting because Brugada syndrome patients can require emergency cardiac stabilization, continuous ECG monitoring, electrophysiology studies, ICD implantation, catheter ablation, and treatment of electrical storms. Access to electrophysiologists, cardiac catheterization laboratories, device implantation facilities, and intensive cardiac care supports the segment's dominant position. Fastest-Growing Subsegment – Specialty Cardiac and Electrophysiology Centers Specialty Cardiac and Electrophysiology Centers account for approximately 22% of the market, equivalent to around USD 59.0 million in 2025, and are projected to record the fastest CAGR of approximately 8.4% during 2026–2032. Such centers increasingly manage complex Brugada syndrome cases requiring detailed arrhythmia risk assessment, ICD follow-up, electro-anatomic mapping, epicardial catheter ablation, and management of recurrent ventricular arrhythmias. Increasing concentration of advanced electrophysiology expertise within specialist centers supports a larger role in Brugada syndrome treatment. By Geography: North America Leads While Asia-Pacific Treatment Expands Leading Subsegment – North America North America holds an estimated 36% share of the Brugada Syndrome Treatment Market, representing approximately USD 96.5 million in 2025, and is projected to expand at a CAGR of approximately 6.7% during 2026–2032. Clinical management follows a risk-based treatment approach in which patients with previous cardiac arrest, documented ventricular arrhythmias, or serious symptoms may receive ICDs, while selected patients with recurrent electrical storms or repeated ICD shocks can undergo catheter ablation. Established electrophysiology infrastructure, cardiac genetic programs, and long-term device-management capabilities keep North America at the forefront of commercial treatment activity. Fastest-Growing Subsegment – Asia-Pacific Asia-Pacific accounts for an estimated 27% share, corresponding to approximately USD 72.4 million in 2025, and is projected to record the fastest regional CAGR of approximately 8.4% during 2026–2032. The region has a particularly strong epidemiological basis for treatment expansion. A global systematic review estimated Brugada syndrome prevalence at approximately 1.8 per 1,000 people in Southeast Asia, among the highest reported regional prevalence levels, while pooled evidence found Brugada syndrome substantially more common among Asian populations than Caucasian populations. Brugada syndrome has also historically been associated with sudden unexpected nocturnal death syndrome in Southeast Asia. A larger identifiable patient pool combined with improving ECG detection, specialist electrophysiology evaluation, ICD access, and catheter ablation capacity is increasing the number of patients able to receive active treatment across the region. What Are the Key Treatment Drivers Shaping the Brugada Syndrome Treatment Market? Implantable Cardioverter-Defibrillator (ICD) Use: ICDs remain the primary treatment for high-risk Brugada syndrome patients, particularly cardiac arrest survivors and patients with serious syncope or documented ventricular arrhythmias. Their role in preventing sudden cardiac death keeps device implantation, generator replacement, lead management, and long-term monitoring at the center of treatment spending. Trigger Avoidance and Fever Management: Preventing arrhythmic episodes is a major part of Brugada syndrome care. Rapid fever treatment and avoidance of medicines known to aggravate Brugada ECG changes or ventricular arrhythmias can reduce emergency events and influence long-term specialist monitoring and patient management. Pharmacological Therapy: Quinidine is used as an alternative or adjunctive therapy in selected patients, particularly when ICD implantation is unsuitable or recurrent arrhythmias persist despite device treatment. Isoproterenol remains important in the acute management of electrical storms and repeated ventricular arrhythmias, supporting a continuing role for drug-based intervention alongside device therapy. Catheter Ablation: Epicardial radiofrequency ablation, particularly targeting abnormal electrical substrates around the right ventricular outflow tract, is becoming increasingly important for patients with recurrent ventricular fibrillation, electrical storms, or repeated appropriate ICD shocks. Clinical evidence showing high rates of freedom from recurrent ventricular arrhythmias is expanding the role of ablation beyond rescue treatment toward a more established part of specialist Brugada syndrome management. Improved Identification of High-Risk Patients: Wider use of ECG testing, provocative drug testing, electrophysiological mapping, and genetic assessment is helping physicians identify patients who may require active intervention rather than monitoring alone. Earlier risk stratification increases the number of patients entering ICD, ablation, pharmacological, and long-term electrophysiology treatment pathways. How Are Defibrillation, Cardiac Mapping, and Remote Monitoring Shaping Competition in the Brugada Syndrome Treatment Market? Boston Scientific: Advancing Brugada Care Through S-ICD Protection and Rhythm Monitoring Boston Scientific is a leading company in the Brugada Syndrome Treatment Market, particularly through its cardiac rhythm management and electrophysiology portfolio. Its EMBLEM MRI S-ICD System is directly relevant to Brugada syndrome because subcutaneous ICDs can provide defibrillation protection without placing transvenous leads inside the heart. Boston Scientific specifically identifies Brugada syndrome and other channelopathies among patient groups in which S-ICD therapy should be strongly considered. Clinical evidence strengthens the company’s position in this treatment area. Data presented from a large multicenter registry involving 450 Brugada syndrome patients treated with S-ICDs showed 90% first-shock efficacy and 100% efficacy by the second shock during spontaneous ventricular arrhythmia episodes. Over a median follow-up of 52 months, 3% of patients received appropriate and effective shocks, while inappropriate shocks occurred in 7% of patients overall and 1.4% at one year. Only 0.7% required antibradycardia pacing after more than four years, supporting the suitability of S-ICD therapy for selected Brugada patients who need sudden-death protection but do not require routine pacing. Beyond defibrillation, Boston Scientific operates across the wider electrophysiology pathway through technologies such as the OPAL HDx Mapping System, LUX-Dx insertable cardiac monitors, BodyGuardian remote cardiac monitors, and transvenous ICD platforms. These technologies support arrhythmia detection, electrical mapping, long-term monitoring, and ventricular defibrillation, giving the company exposure across several stages of Brugada syndrome management rather than only the initial ICD implantation procedure. Other Relevant Companies and Their Roles Medtronic: Provides ICD systems, cardiac monitoring, mapping, and catheter-ablation technologies used in ventricular arrhythmia management; its Cobalt XT ICD platform also incorporates adaptive antitachycardia pacing technology for ventricular tachycardia treatment. Abbott: Supports the electrophysiology and ablation side of Brugada care through the EnSite X/EnSite cardiac mapping platforms, Advisor HD Grid mapping catheters, and ablation catheters, which help physicians identify abnormal electrical substrates before targeted ablation. Johnson & Johnson MedTech/Biosense Webster: Participates mainly through electroanatomical mapping and catheter-ablation technologies, supporting complex electrophysiology procedures in patients with recurrent ventricular arrhythmias. BIOTRONIK: Supplies implantable defibrillators, cardiac rhythm-management devices, leads, and remote monitoring technologies, supporting long-term management of patients requiring protection from potentially fatal ventricular arrhythmias. MicroPort CRM: Provides ICDs and cardiac rhythm-management systems, contributing to device-based prevention of sudden cardiac death among selected high-risk arrhythmia patients. Analyst Commentary: Where Will Integrated Rhythm Care Create the Next Brugada Treatment Opportunity? The Brugada Syndrome Treatment Market is moving beyond conventional ICD-based risk protection toward a more integrated arrhythmia-management approach combining advanced electrophysiology, epicardial substrate ablation, genetic assessment, and continuous cardiac monitoring. The strongest opportunities are emerging around wider use of high-resolution cardiac mapping, improved identification of high-risk patients, greater adoption of catheter ablation for recurrent ventricular fibrillation, and next-generation defibrillation systems designed to reduce lead-related complications. Brugada Syndrome Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 268 Million Revenue Forecast in 2032 USD 436 Million Overall Growth Rate CAGR of 7.2% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Diagnosis Method, By End User, By Geography By Treatment Type Implantable Cardioverter-Defibrillators (ICDs), Epicardial Radiofrequency Ablation, Antiarrhythmic Drug Therapy, Emergency and Supportive Rhythm Management By Diagnosis Method Electrocardiography and Provocative Drug Testing, Electrophysiological Testing and Mapping, Genetic Testing By End User Hospitals, Specialty Cardiac and Electrophysiology Centers, Ambulatory and Specialized Outpatient Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Improved ECG-based detection, genetic and family screening, wider access to electrophysiology care, increasing ICD adoption, growing use of catheter ablation, improved high-risk patient identification, and increasing awareness of Brugada syndrome and sudden cardiac death prevention Customization Option Available upon request Frequently Asked Question About This Report Q1: What factors are encouraging treatment adoption in the market? A1: Adoption is increasing as more high-risk patients are identified through ECG testing, genetic assessment, and electrophysiology evaluation. Wider access to ICD implantation and specialist arrhythmia care is also bringing more patients into active treatment. Q2: What are the major treatment trends shaping the industry? A2: Treatment is becoming more integrated, combining ICD protection with catheter ablation, antiarrhythmic therapy, genetic assessment, and long-term rhythm monitoring. This is expanding care beyond device implantation alone. Q3: Why is catheter ablation gaining importance in the market? A3: Catheter ablation is gaining importance for patients with recurrent ventricular fibrillation, electrical storms, or repeated ICD shocks. It targets abnormal electrical tissue and can reduce future arrhythmic episodes in selected high-risk patients. Q4: How is diagnostic advancement influencing the industry? A4: Better ECG interpretation, provocative drug testing, electro-anatomic mapping, and genetic testing are improving identification of concealed and high-risk cases. Earlier diagnosis can lead to faster decisions around monitoring, ICD therapy, or ablation. Q5: Which region is expected to record the fastest growth in the market? A5: Asia-Pacific is projected to record the fastest regional CAGR of around 8.4% during 2026–2032. Higher reported prevalence in parts of Southeast Asia and improving electrophysiology infrastructure are supporting treatment growth. Q6: What opportunities could shape the future of the industry? A6: Strong opportunities are emerging around high-resolution mapping, next-generation defibrillators, remote cardiac monitoring, genetic risk assessment, and wider use of ablation. These technologies can improve risk identification and reduce recurrent arrhythmic events. Sources: NIH/MedlinePlus – Brugada Syndrome Prevalence, 8–10× Higher Frequency in Men, SCN5A Genetics MedlinePlus – Brugada Syndrome NIH/NCBI GeneReviews – ICDs, Quinidine, Isoproterenol, ECG/Genetic Testing and Brugada Management NCBI GeneReviews – Brugada Syndrome HRS/EHRA/APHRS – Brugada Syndrome Treatment Consensus: ICD, Quinidine, Isoproterenol and Catheter Ablation Inherited Arrhythmia Syndrome Consensus Recommendations Orphanet – Brugada Syndrome Prevalence, Regional Differences and Male Predominance Orphanet – Brugada Syndrome Boston Scientific – EMBLEM MRI S-ICD for Sudden Cardiac Death Protection Boston Scientific EMBLEM MRI S-ICD JACC / PubMed – 450-Patient Brugada S-ICD Registry: 90% First-Shock and 100% Second-Shock Efficacy PubMed – S-ICD Therapy in Brugada Syndrome Abbott – EnSite X and Advisor HD Grid High-Density Electrophysiology Mapping Abbott Advisor HD Grid X Mapping Catheter Medtronic – Cobalt XT ICD for Life-Threatening Ventricular Arrhythmias Medtronic Cobalt XT ICD Table of Contents - Global Brugada Syndrome Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Diagnosis Method, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Diagnosis Method, End User, and Region Market Share Analysis Leading Players by Revenue and Market Position Market Position Analysis by Treatment Type, Diagnosis Method, and End User Investment Opportunities in the Brugada Syndrome Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in ICD Protection, Epicardial Radiofrequency Ablation, Electrophysiological Mapping, Genetic Testing, Cardiac Monitoring, and Advanced Rhythm Management Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Brugada Syndrome Diagnosis, Sudden Cardiac Death Prevention, ICD Protection, and Advanced Electrophysiology Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Clinical Risk-Stratification Factors Role of Implantable Cardioverter-Defibrillators, Epicardial Ablation, Electrophysiological Mapping, Genetic Testing, and Cardiac Monitoring in Market Expansion Risk Assessment, Trigger Avoidance, Fever Management, Remote Monitoring, and Long-Term Rhythm Management Trends Global Brugada Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Implantable Cardioverter-Defibrillators (ICDs) Epicardial Radiofrequency Ablation Antiarrhythmic Drug Therapy Emergency and Supportive Rhythm Management Market Analysis by Diagnosis Method: Electrocardiography and Provocative Drug Testing Electrophysiological Testing and Mapping Genetic Testing Market Analysis by End User: Hospitals Specialty Cardiac and Electrophysiology Centers Ambulatory and Specialized Outpatient Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Brugada Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis Method, and End User Country-Level Breakdown: United States Canada Mexico Europe Brugada Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis Method, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Brugada Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis Method, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Brugada Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis Method, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Brugada Syndrome Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Diagnosis Method, and End User Country-Level Breakdown: GCC Countries Saudi Arabia UAE South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Boston Scientific Corporation Medtronic plc Abbott Laboratories Johnson & Johnson MedTech / Biosense Webster BIOTRONIK SE & Co. KG MicroPort CRM Koninklijke Philips N.V. GE HealthCare Technologies Inc. iRhythm Technologies, Inc. Lepu Medical Technology (Beijing) Co., Ltd. Competitive Landscape and Strategic Insights Benchmarking Based on ICD Platform Capabilities, Defibrillation Protection, Electrophysiological Mapping, Catheter Ablation Technology, Remote Cardiac Monitoring, and Rhythm-Management Expertise Device Safety, Clinical Evidence, Electrophysiology Capability, and Long-Term Monitoring Analysis Subcutaneous and Transvenous ICD Positioning Epicardial Ablation and Ventricular Arrhythmia Management Competitiveness Electro-Anatomic Mapping and Substrate Identification Strategy Analysis Genetic Assessment, ECG Detection, and Precision Risk-Stratification Support Remote Monitoring and Long-Term Device Management Strategy Analysis Integrated Defibrillation, Mapping, Ablation, and Monitoring Ecosystem Positioning Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Diagnosis Method, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Brugada Syndrome Treatment Vendors ICD, Ablation, Electrophysiology Mapping, Monitoring, and Clinical Risk-Management Analysis Technology Adoption Trends Across ICD Protection, Epicardial Radiofrequency Ablation, Electrophysiological Testing and Mapping, Genetic Testing, and Cardiac Monitoring List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Position Growth Strategies Adopted by Key Players Market Segmentation by Treatment Type, Diagnosis Method, End User, and Region (2025 vs. 2032) Global Brugada Syndrome Treatment Ecosystem and Value Chain Analysis ICD Protection, Cardiac Mapping, Catheter Ablation, and Remote Monitoring Technology Landscape